Pretreatment stromal CD4+ T-cell density predicts favorable response to total neoadjuvant therapy in locally advanced rectal cancer.
A simple immune cell count from tumor tissue before treatment predicts which rectal cancer patients will respond well to neoadjuvant therapy.
Higher pretreatment stromal CD4+ T-cell density significantly predicts pathological response to total neoadjuvant therapy in locally advanced rectal cancer, supporting its utility as an accessible tissue biomarker for treatment stratification. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- prospective_cohort
- Category
- precision_oncology
- Maturity
- Validated
- Journal
- Biomolecules and Biomedicine
Why it surfaced
Prospective validation of CD4+ T-cell density as a predictive biomarker for total neoadjuvant therapy response in rectal cancer; actionable for precision oncology treatment selection.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.